Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 6
Submit an article Journal homepage
328
Views
49
CrossRef citations to date
0
Altmetric
Review

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma

David A Reardon Center for Neuro-Oncology, Dana–Farber/Brigham and Women’s Cancer Center, Boston, MA, USA. [email protected]; Center for Neuro-Oncology, Dana–Farber/Brigham and Women’s Cancer Center, Boston, MA, USA. [email protected]
,
Kai W Wucherpfennig Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA, USA; Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA, USA
,
Gordon Freeman Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA, USA; Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA, USA
,
Catherine J Wu Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana–Farber/Brigham and Women’s Cancer Center, Boston, MA, USA; Department of Cancer Immunology and AIDS, Dana–Farber Cancer Institute, Boston, MA, USA; Department of Medical Oncology, Dana–Farber/Brigham and Women’s Cancer Center, Boston, MA, USA
,
E Antonio Chiocca Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA, USA; Department of Neurosurgery, Brigham and Women’s Hospital, Boston, MA, USA
,
Patrick Y Wen Center for Neuro-Oncology, Dana–Farber/Brigham and Women’s Cancer Center, Boston, MA, USA; Division of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; Center for Neuro-Oncology, Dana–Farber/Brigham and Women’s Cancer Center, Boston, MA, USA; Division of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA
,
William T Curry Jr Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA
,
Duane A Mitchell Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA; Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA
,
Peter E Fecci Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA; Department of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA
,
John H Sampson Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA; Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC, USA
&
Glenn Dranoff Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; Department of Medical Oncology and Cancer Vaccine Center, Dana–Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
 show all
Pages 597-615 | Published online: 09 Jan 2014
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Outcome for glioblastoma (GBM), the most common primary CNS malignancy, remains poor. The overall survival benefit recently achieved with immunotherapeutics for melanoma and prostate cancer support evaluation of immunotherapies for other challenging cancers, including GBM. Much historical dogma depicting the CNS as immunoprivileged has been replaced by data demonstrating CNS immunocompetence and active interaction with the peripheral immune system. Several glioma antigens have been identified for potential immunotherapeutic exploitation. Active immunotherapy studies for GBM, supported by preclinical data, have focused on tumor lysate and synthetic antigen vaccination strategies. Results to date confirm consistent safety, including a lack of autoimmune reactivity; however, modest efficacy and variable immunogenicity have been observed. These findings underscore the need to optimize vaccination variables and to address challenges posed by systemic and local immunosuppression inherent to GBM tumors. Additional immunotherapy strategies are also in development for GBM. Future studies may consider combinatorial immunotherapy strategies with complimentary actions.

Financial & competing interests disclosure

JH Sampson has a consultancy, honoraria and research funding with Celldex Therapeutics. G Freeman has a consultancy with CoStim Pharmaceuticals and grants/patents/pending royalties with Bristol-Myers Squibb/Medarex, Roche/Genentech, Merck, EMD-Serono, Boehringer-Ingelheim, GlaxoSmithKline and CoStim Pharmaceuticals. DA Mitchell and JH Sampson have grants/patents/pending royalties through Celldex Therapeutics and Annias Immunotherapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later
PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.